Biogen Inc. (BIIB)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow BIIB in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on BIIB and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
BIIB at a glance
Key statistics
$35.92B
Market capitalization
- Previous close
- $243.10
- Open
- $242.27
- Day range
- $240.18 – $243.18
- Volume
- 355.6K
- Average volume (30 sessions)
- 1.19M
- Shares outstanding
- 147.75M
- Price / earnings
- 43.0
- Earnings per share
- $5.65
- Price / book
- 1.9
- Price / sales
- 3.6
- Beta (1 year, vs SPY)
- 0.32
Where the price sits in its year
52-week range
98% of the range
- Below the 52-week high
- -1.1%
- Above the 52-week low
- +75.4%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $227.72+6.8%
- 50-day average
- $220.94+10.0%
- 200-day average
- $198.44+22.5%
In the band above 70 that convention calls overbought. Strong trends can stay there for weeks.
+6.2%
1 week
+11.0%
1 month
+22.9%
3 months
+38.1%
Year to date
+70.0%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with BIIB
BIIB on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on BIIB.
See the plans →
Every planScreen names like BIIB
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on BIIB
Put BIIB on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on BIIB
See whether there is an open premium alert on BIIB, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
BIIB headlines
- Biogen Completes Acquisition of RayThera Inc.
GlobeNewswire Inc. · Aug 6, 2026
- Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Benzinga · Jun 18, 2026
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
GlobeNewswire Inc. · Jun 17, 2026
- Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish
Investing.com · May 22, 2026
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
GlobeNewswire Inc. · May 21, 2026
- Why Is Biogen Stock Falling Thursday?
Benzinga · May 14, 2026
- Biogen Completes Acquisition of Apellis Pharmaceuticals
Benzinga · May 14, 2026
- Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
Benzinga · May 8, 2026
SEC Form 4, most recent first
Insider filings
Godbout Sean
−27
Chief Accounting Officer · Option exercise
· Oct 2, 2026
Godbout Sean
+27
Chief Accounting Officer · Option exercise
· Oct 2, 2026
Godbout Sean
+985
Chief Accounting Officer · Grant or award
· Oct 1, 2026
Godbout Sean
−8
Chief Accounting Officer · Shares withheld for tax
$1.76K · Oct 2, 2026
Parini Michael
+7.4K
Chief Legal Officer · Grant or award
· Sep 1, 2026
Minor Lloyd
−593
Director · Open-market sale
$119.17K · Aug 4, 2026
Minor Lloyd
−593
Director · Open-market sale
$120.58K · Aug 3, 2026
Pangalos Menelas N
−2.4K
Director · Option exercise
· Jun 9, 2026
About Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Employees
- 7,500
- Listed since
- Sep 17, 1991
- Website
- biogen.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.